香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 （於百慕達註冊成立之有限公司） （股份代號：00152） 自願性公告 華南物流園項目一期轉型升級進展 茲提述本公司日期為 2023 年 10 月 31 日、2024 年 12 月 30 日及 2025 年 7 月 25 日的公告（ 「 該 等 公 告 」 ） ，內容有關（其中包括）（1）本集 團就開展華南轉型項目與深圳市龍華區城市更新和土地整備局 、 深 圳 市 龍 華 區 民 治 街 道 辦 事 處 及 市 規 資 局 龍 華 局 簽 訂 了 土 地 整 備 協 議 ， 各 方 同 意 綜 合 採 用 安 排 留 用 土 地 和 貨 幣 補 償 的 方 式 實 施 該 項 目 。 華 南 物 流 公 司 作 為 原 土 地 使 用 權 人 ， 可 在 華 南 物 流 園 內 留 用 面 積 約 108,749 平 方米的留用土地；（2）第一期留用土地（即 02-20-04 號地塊）的相關 安排於 20 ...

Group 1 - The 2025 Shenzhen International High-Performance Medical Device and Innovative Pharmaceutical Exhibition showcased over 300 global companies and more than 1,000 innovative products, highlighting China's transition from "technology catch-up" to "innovation leadership" in the medical device industry [1] - The annual innovation results from the National High-Performance Medical Device Innovation Center revealed 11 assessment results, including the "Top 100 Emerging Enterprises" focusing on high-end medical imaging and surgical robots, with 100 companies engaging in 339 industry-academia-research collaborations and undertaking 133 research projects [1] - The assessment introduced three innovation indices focusing on emerging fields such as AI-assisted diagnosis and ophthalmic devices, indicating significant breakthroughs in globally pioneering products like vascular interventional surgical robots and critical materials in "bottleneck" areas [1] Group 2 - The report "Trends in Medical Equipment Patents in China (2025)" indicated that by 2025, China will have over 2.8 million medical equipment patent applications, maintaining the global lead with a 34.1% share, and a year-on-year growth of 3.2%, with a ten-year compound growth rate of 15.5%, both double the global average [2] - Shenzhen contributed 140,000 patent applications, accounting for 43.1% of Guangdong Province's total of 325,000 applications, showcasing the city's significant role in medical device innovation [2] - Experts noted that the medical device industry has shifted from imitation to independent innovation, achieving a level of development comparable to global standards, with future devices expected to integrate various technologies for smarter, personalized, and more active solutions to health and disease [2]

Group 1: Airline Industry - Goldman Sachs forecasts that international demand will rise while supply constraints persist, leading to an expected return on equity (ROE) of 22% for airlines by 2027, surpassing the industry cycle average [1] - Despite risks associated with Japan in the first half of the year, the outlook for airline stocks remains positive, with expectations for further increases in ticket prices; preferred stocks include Air China H-shares and China Eastern Airlines A-shares [1] Group 2: Container Shipping - The recovery in supply has led Goldman Sachs to adopt a more cautious stance on container shipping, predicting a compression in industry profit margins [1] - New ship orders this year have exceeded expectations, resulting in an order-to-existing capacity ratio of 33% [1] - Potential reopening of the Red Sea may pose additional downside risks, potentially releasing about 10% of effective capacity, which could lead to cash consumption issues for COSCO Shipping Holdings [1] Group 3: Oil Tankers - Goldman Sachs maintains an optimistic outlook for oil tankers, expecting spot freight rates to rise further during the ongoing upward cycle in 2026 [1] - The process of China's oil reserve buildup may take up to a year, longer than the market's expectation of three months, while effective capacity is predicted to grow by only 1% [1] - COSCO Shipping Energy is expected to benefit due to its significant exposure to oil tankers and the Chinese import market [1]

Group 1 - The 2025 Shenzhen International High-Performance Medical Device and Innovative Pharmaceutical Exhibition showcased over 1,000 innovative products from more than 300 leading global pharmaceutical and medical device companies, covering the latest achievements in high-end medical devices, innovative drugs, and AI applications [1] - The exhibition featured ten major exhibition areas, including medical imaging, emergency rescue, rehabilitation, and artificial intelligence, creating a comprehensive platform for display, communication, and collaboration within the pharmaceutical and medical device industry [1] - The event was organized by the China Medical Equipment Association, the National High-Performance Medical Device Innovation Center, and the Shenzhen Medical Device Industry Association [1] Group 2 - The exhibition highlighted advancements in future medical technologies, such as robotic surgery, advanced imaging equipment, brain-machine interfaces, and AI-assisted rehabilitation tools, demonstrating the potential of these innovations [2] - Notable products included the multi-port and single-port laparoscopic surgical robots from Qingfeng Medical, and an AI-based drug-device research public service platform from Particle Technology, which significantly reduces traditional research and development timelines [2] - Major companies like Mindray and Siemens showcased their cutting-edge medical equipment, emphasizing the clinical applications and enhanced imaging capabilities of their products [2] Group 3 - The pharmaceutical and medical device industry in Shenzhen has seen continuous growth, with an industry output value reaching 157.6 billion yuan in 2024, including over 102.8 billion yuan from medical devices, maintaining the top position in the country for ten consecutive years [3] - Shenzhen has nurtured 35 listed companies and 143 enterprises with an output value exceeding 100 million yuan in the pharmaceutical and medical device sector, with leading firms such as Mindray and Xintai emerging in various market segments [3] - The exhibition served as a platform for the release of significant collaborations and innovations, including a $1.64 billion strategic partnership between Pruijin and Kite for in vivo CAR-T therapies, showcasing the global push for cell therapy technologies [3]

Core Insights - The "2026 Shenzhen International Composite Materials Industrial Technology Exhibition" will be held from June 10-12, 2026, at the Shenzhen International Convention and Exhibition Center, focusing on "Technological Innovation, Leading the Future" [1] Group 1: Exhibition Overview - The exhibition aims to enhance service quality and expand promotional efforts to attract more domestic and international exhibitors and professional visitors [1] - It will showcase renowned domestic and international companies, covering the entire supply chain of composite materials, including raw materials, production technologies, quality control, and energy-saving applications [1] - The event will feature various formats such as exhibitions, forums, and promotional meetings to foster industry cooperation and development [1] Group 2: Exhibitor Categories - Raw materials and production equipment will include various resins (unsaturated, epoxy, vinyl, phenolic), fibers (glass, carbon, basalt, aramid, natural fibers), adhesives, additives, fillers, colorants, and pre-impregnated materials [5] - Composite production technologies and equipment will encompass new forming technologies such as injection, winding, molding, and vacuum infusion, along with mechanical processing equipment and mold design [5] - Final products and applications will cover sectors like corrosion engineering, construction, automotive, aerospace, defense, chemical, renewable energy, and daily life products [5]

Group 1 - The core point of the article is that Shenzhen International (00152) has successfully introduced new investors into its associate company, Shenzhen Airlines, through a public offering, resulting in a significant dilution of its ownership stake [1] - Shenzhen Airlines has signed a capital increase agreement with new investors, including China National Aviation Holding and Kunhang Investment, with respective contributions of approximately RMB 20.82 billion and RMB 20 billion [1] - Following the capital increase, Shenzhen Airlines' registered capital will increase, and Shenzhen International's ownership stake will be diluted from 49% to approximately 28.09%, while China National Aviation and Kunhang Investment will hold 51% and approximately 20.91% of the shares, respectively [1] Group 2 - The stock price of Shenzhen International closed at 8.39 yuan, up 0.48% from the previous trading day, with a trading volume of 31.90 million yuan [1] - The stock has seen a 52-week high of 8.74 yuan and a low of 6.16 yuan [1] - The company will announce further developments regarding the capital increase in accordance with listing rules when significant progress occurs [1]

Group 1 - Shenzhen International (00152.HK) announced that its associate company, Shenzhen Airlines, plans to conduct a phased capital increase totaling 16 billion RMB [1] - The group has decided not to participate in the capital increase, which will introduce Kunhang Investment as a new investor through a public bidding process [1] - The capital increase agreement and related documents are set to be signed on December 18, 2025, with China National Aviation and Kunhang Investment contributing approximately 2.082 billion RMB and 2 billion RMB respectively in the first phase [1] Group 2 - Following the completion of the first phase of the capital increase, the group's stake in Shenzhen Airlines will be diluted from 49% to approximately 28.09% [1] - China National Aviation and Kunhang Investment will hold 51% and approximately 20.91% of Shenzhen Airlines respectively, which will continue to be an associate company of Shenzhen International [1] - Further dilution of the group's stake is expected as China National Aviation and Kunhang Investment will sign relevant agreements for subsequent capital increases in due course [1]

智通财经APP讯，深圳国际(00152)发布公告，有关公司的联营公司深圳航空拟分阶段进行增资扩股，合 共增资人民币160亿元，而集团决定不参与增资。深圳航空已通过公开挂牌方式成功引入深圳市鲲航投 资合伙企业(有限合伙)作为新投资者，并于2025年12月18日签署增资协议及相关文件。据此，中国国航 及鲲航投资将分别出资约人民币20.82亿元及人民币20亿元，以认购深圳航空的新增注册资本。于第一 阶段增资完成后，集团所持深圳航空的股权将由49%被摊薄至约28.09%，中国国航及鲲航投资将分别持 有深圳航空51%及约20.91%的股权，深圳航空将继续为公司的联营公司。中国国航及鲲航投资将就后续 增资适时签署相关协议，集团所持深圳航空的股权预计将进一步被摊薄。 ...

智通财经APP讯，深圳国际(00152)发布公告，有关公司的联营公司深圳航空拟分阶段进行增资扩股，合 共增资人民币160亿元，而集团决定不参与增资。深圳航空已通过公开挂牌方式成功引入深圳市鲲航投 资合伙企业(有限合伙)作为新投资者，并于2025年12月18日签署增资协议及相关文件。据此，中国国航 及鲲航投资将分别出资约人民币20.82亿元及人民币20亿元，以认购深圳航空的新增注册资本。于第一 阶段增资完成后，集团所持深圳航空的股权将由49%被摊薄至约28.09%，中国国航及鲲航投资将分别持 有深圳航空51%及约20.91%的股权，深圳航空将继续为公司的联营公司。中国国航及鲲航投资将就后续 增资适时签署相关协议，集团所持深圳航空的股权预计将进一步被摊薄。 ...

深圳航空已通过公开挂牌方式成功引入深圳市鲲航投资合伙企业(有限合伙)("鲲航投资")作为新投资 者，并于2025年12月18日签署增资协议及相关文件。据此，中国国航及鲲航投资将分别出资约人民币 20.82亿元及人民币20亿元，以认购深圳航空的新增注册资本("第一阶段增资")。于第一阶段增资完成 后，集团所持深圳航空的股权将由49%被摊薄至约28.09%，中国国航及鲲航投资将分别持有深圳航空 51%及约20.91%的股权，深圳航空将继续为公司联营公司。中国国航及鲲航投资将就后续增资适时签署 相关协议，集团所持深圳航空之股权预计将进一步被摊薄。 格隆汇12月18日丨深圳国际(00152.HK)公布，有关公司联营公司深圳航空拟分阶段进行增资扩股，合共 增资人民币160亿元，而集团决定不参与增资。 来源：格隆汇APP ...